Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Hereditary Spherocytosis Treatment & Management

  • Author: Gus Gonzalez, MD; Chief Editor: Emmanuel C Besa, MD  more...
 
Updated: Oct 13, 2015
 

Approach Considerations

Neonates with severe hyperbilirubinemia caused by hereditary spherocytosis (HS) are at risk for kernicterus. These infants should be treated with phototherapy and/or exchange transfusion as clinically indicated.

Aplastic crises occasionally can cause the hemoglobin level to fall because of ongoing destruction of spherocytes that is not balanced by new red blood cell (RBC) production. RBC transfusions often are necessary in these cases.

Folic acid is required to sustain erythropoiesis. Patients with HS are instructed to take supplementary folic acid for life in order to prevent a megaloblastic crisis. During the first 6 years of life, if patients have compensated anemia, are growing well, and can keep up with their peers in most activities, limiting folic acid supplementation to 1 mg/d is prudent.

Splenectomy is the definitive treatment for HS.[2] Except in the unusual autosomal recessive variant of HS, splenectomy usually eliminates hemolysis and the associated signs and symptoms.[3] Splenectomy may fail to control HS because of an accessory spleen, accidental autotransplantation of splenic tissue into the peritoneum during surgery, another hemolytic disorder, or splenosis.

Indications for splenectomy are not always clear.[11] Little doubt exists that patients with more severe anemia and symptoms and complications of HS should undergo splenectomy. By the same token, splenectomy can be deferred safely in patients with mild uncomplicated HS (hemoglobin level >11 g/dL). No good studies have been performed that provide a basis for clinical judgments in patients with moderate asymptomatic HS (hemoglobin level 8-11 g/dL).

Children who are candidates for splenectomy include those with severe HS requiring red cell transfusions and those with moderate HS who manifest growth failure or other signs and symptoms of anemia. Splenectomy for children with HS should not be performed until the child is older than 6 years, to reduce the risk of infections with encapsulated bacteria.

An interesting alternative approach in pediatric patients has been the use of partial splenectomy to retain splenic immunologic function while at the same time reducing the rate of hemolysis.[12, 13] This appears to both control hemolysis and preserve splenic function.

Red cell survival improves significantly after splenectomy but does not become absolutely normal. The mean corpuscular volume (MCV) usually falls, but the mean corpuscular hemoglobin concentration (MCHC) does not change significantly.

In children with HS who underwent total or partial splenectomy, a review found that the hemoglobin concentration increased from 10.1 ± 1.8 g/dL at baseline to 12.8 ± 1.6 g/dL at 52 weeks postoperatively. In addition, splenectomry resulted in a decrease in reticulocyte counts and bilirubin levels as well as control of symptoms.[14]

Other postsplenectomy blood changes include the following:

  • Increased hemoglobin level
  • Decreased reticulocyte count
  • Leukocytosis
  • Thrombocytosis

On the peripheral blood smear, spherocytes continue to appear. Expected changes on peripheral blood smears include the appearance of Howell-Jolly inclusion bodies and target cells. Absence of Howell-Jolly bodies on the peripheral blood smear in splenectomized patients may indicate the presence of functional splenic activity.

Fatal sepsis caused by capsulated organisms (eg, Streptococcus pneumoniae, Haemophilus influenzae) is a recognized complication in children who have had a splenectomy. The estimated rate of mortality from sepsis in these children is approximately 200 times greater than that expected in the general population. Although most septic episodes have been observed in children whose spleens were removed in the first years of life, older children and adults also are susceptible.

Vaccination against pneumococcus and H influenzae must be administered to patients prior to splenectomy and, indeed, probably to all patients with severe HS. If a partial splenectomy is performed, splenic function is preserved and vaccinations may be delayed until after surgery; however, the long-term data are not well established.

Bilirubin gallstones are found in approximately 50% of patients with HS and frequently are present in patients with very mild disease. Therefore, periodic ultrasonic evaluation of the gallbladder should be performed.

If surveillance ultrasound examinations reveal gallstones, performing a prophylactic laparoscopic cholecystectomy seems reasonable. This procedure helps prevent significant biliary tract disease and, in some patients with mild HS, helps avoid the need for splenectomy. In patients with bilirubin stones who are candidates for splenectomy, a simultaneous cholecystectomy may eliminate future complications and the need for a second operative procedure.

Next

Splenectomy

Generally, the treatment of HS involves presplenectomy care, splenectomy, and management of postsplenectomy complications. In pediatric cases, splenectomy ideally should not be performed until a child is older than 6 years because of the increased incidence of postsplenectomy infections with encapsulated organisms such as S pneumoniae and H influenzae in young children. Partial splenectomies are increasingly used in pediatric patients, as this approach appears to both control hemolysis and preserve splenic function.

A retrospective review by Abdullah et al of splenectomy for HS in over 1650 children found that the morbidity and mortality are low, and that performance of concurrent cholecystectomy and/or appendectomy is safe. In addition, Abdullah et al found that of 13 potentially avoidable complications identified as pediatric quality indicators by the Agency for Healthcare Research and Quality (AHRQ), none occurred in more than 1% of the splenectomized children.[3]

Previous
Next

Consultations

If the diagnosis of HS is unclear after routine testing or the patient has severe episodes of hemolysis, consultation with a hematologist is warranted because the patient may have a variant of HS or more than one hemolytic disease. A hematologist also may provide treatment advice regarding iron overload for patients who have an extensive transfusion history or for those who have been receiving prolonged oral iron supplementation.

Patients with HS who have recurring episodes of severe hemolysis should be evaluated by a surgeon for possible splenectomy, because splenectomy provides the greatest chance for control of their disease. A partial splenectomy can be considered if a surgeon experienced in this procedure is available. Another reason for consulting a surgeon is for the complications of gallstone formation and for the prevention of gallstones in those patients with continued hemolysis.

Previous
Next

Long-term Monitoring

Lifelong folic acid supplementation is recommended for patients with HS because of their low levels of chronic hemolysis. This is especially true for those who have not undergone splenectomy. After splenectomy, all patients should have immunizations updated as needed, especially those covering encapsulated organisms. Vaccination against S pneumonia and H influenzae is of particular importance.

Previous
 
 
Contributor Information and Disclosures
Author

Gus Gonzalez, MD Medical Oncologist, The Center for Cancer and Blood Disorders

Gus Gonzalez, MD is a member of the following medical societies: American College of Physicians-American Society of Internal Medicine

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Ronald A Sacher, MB, BCh, FRCPC, DTM&H Professor, Internal Medicine and Pathology, Director, Hoxworth Blood Center, University of Cincinnati Academic Health Center

Ronald A Sacher, MB, BCh, FRCPC, DTM&H is a member of the following medical societies: American Association for the Advancement of Science, American Association of Blood Banks, American Society for Clinical Pathology, American Society of Hematology, College of American Pathologists, International Society on Thrombosis and Haemostasis, Royal College of Physicians and Surgeons of Canada, American Clinical and Climatological Association, International Society of Blood Transfusion

Disclosure: Serve(d) as a speaker or a member of a speakers bureau for: GSK Pharmaceuticals,Alexion,Johnson & Johnson Talecris,,Grifols<br/>Received honoraria from all the above companies for speaking and teaching.

Chief Editor

Emmanuel C Besa, MD Professor Emeritus, Department of Medicine, Division of Hematologic Malignancies and Hematopoietic Stem Cell Transplantation, Kimmel Cancer Center, Jefferson Medical College of Thomas Jefferson University

Emmanuel C Besa, MD is a member of the following medical societies: American Association for Cancer Education, American Society of Clinical Oncology, American College of Clinical Pharmacology, American Federation for Medical Research, American Society of Hematology, New York Academy of Sciences

Disclosure: Nothing to disclose.

Additional Contributors

Paul Schick, MD Emeritus Professor, Department of Internal Medicine, Jefferson Medical College of Thomas Jefferson University; Research Professor, Department of Internal Medicine, Drexel University College of Medicine; Adjunct Professor of Medicine, Lankenau Hospital

Paul Schick, MD is a member of the following medical societies: American College of Physicians, American Society of Hematology

Disclosure: Nothing to disclose.

Acknowledgements

E Randy Eichner, MD Professor, Department of Internal Medicine, University of Oklahoma Health Sciences Center

E Randy Eichner, MD is a member of the following medical societies: Alpha Omega Alpha, American College of Sports Medicine, American Medical Society for Sports Medicine, and American Society of Hematology

Disclosure: Nothing to disclose.

References
  1. Bianchi P, Fermo E, Vercellati C, Marcello AP, Porretti L, Cortelezzi A, et al. Diagnostic power of laboratory tests for hereditary spherocytosis: a comparison study on 150 patients grouped according to the molecular and clinical characteristics. Haematologica. 2011 Nov 4. [Medline].

  2. [Guideline] Bolton-Maggs PH, Langer JC, Iolascon A, Tittensor P, King MJ. Guidelines for the diagnosis and management of hereditary spherocytosis - 2011 update. Br J Haematol. 2012 Jan. 156(1):37-49. [Medline].

  3. Abdullah F, Zhang Y, Camp M, Rossberg MI, Bathurst MA, Colombani PM, et al. Splenectomy in hereditary spherocytosis: Review of 1,657 patients and application of the pediatric quality indicators. Pediatr Blood Cancer. 2009 Jul. 52(7):834-7. [Medline].

  4. Perrotta S, Della Ragione F, Rossi F, et al. {beta}-spectrinBari: a truncated {beta}-chain responsible for dominant hereditary spherocytosis. Haematologica. 2009 Jul 16. epub ahead of print. [Medline]. [Full Text].

  5. Maciag M, Plochocka D, Adamowicz-Salach A, Burzynska B. Novel beta-spectrin mutations in hereditary spherocytosis associated with decreased levels of mRNA. Br J Haematol. 2009 Aug. 146(3):326-32. [Medline].

  6. Zaninoni A, Vercellati C, Imperiali FG, Marcello AP, Fattizzo B, Fermo E, et al. Detection of red blood cell antibodies in mitogen-stimulated cultures from patients with hereditary spherocytosis. Transfusion. 2015 Aug 10. [Medline].

  7. Perrotta S, Gallagher PG, Mohandas N. Hereditary spherocytosis. Lancet. 2008 Oct 18. 372(9647):1411-26. [Medline].

  8. Wang C, Cui Y, Li Y, Liu X, Han J. A systematic review of hereditary spherocytosis reported in Chinese biomedical journals from 1978 to 2013 and estimation of the prevalence of the disease using a disease model. Intractable Rare Dis Res. 2015 May. 4 (2):76-81. [Medline]. [Full Text].

  9. Teunissen M, Hijmans CT, Cnossen MH, Bronner MB, Grootenhuis MA, Peters M. Quality of life and behavioral functioning in Dutch pediatric patients with hereditary spherocytosis. Eur J Pediatr. 2014 Apr 16. [Medline].

  10. Christensen RD, Yaish HM, Gallagher PG. A pediatrician's practical guide to diagnosing and treating hereditary spherocytosis in neonates. Pediatrics. 2015 Jun. 135 (6):1107-14. [Medline].

  11. Casale M, Perrotta S. Splenectomy for hereditary spherocytosis: complete, partial or not at all?. Expert Rev Hematol. 2011 Dec. 4(6):627-35. [Medline].

  12. Morinis J, Dutta S, Blanchette V, Butchart S, Langer JC. Laparoscopic partial vs total splenectomy in children with hereditary spherocytosis. J Pediatr Surg. 2008 Sep. 43(9):1649-52. [Medline].

  13. Grace RF, Mednick RE, Neufeld EJ. Compliance with immunizations in splenectomized individuals with hereditary spherocytosis. Pediatr Blood Cancer. 2009 Jul. 52(7):865-7. [Medline].

  14. Rice HE, Englum BR, Rothman J, Leonard S, Reiter A, et al. Clinical outcomes of splenectomy in children: report of the splenectomy in congenital hemolytic anemia registry. Am J Hematol. 2015 Mar. 90 (3):187-92. [Medline].

  15. Agre P, Asimos A, Casella JF, McMillan C. Inheritance pattern and clinical response to splenectomy as a reflection of erythrocyte spectrin deficiency in hereditary spherocytosis. N Engl J Med. 1986 Dec 18. 315(25):1579-83. [Medline].

  16. Costa FF, Agre P, Watkins PC, et al. Linkage of dominant hereditary spherocytosis to the gene for the erythrocyte membrane-skeleton protein ankyrin. N Engl J Med. 1990 Oct 11. 323(15):1046-50. [Medline].

  17. Gallagher PG. Hematologically important mutations: ankyrin variants in hereditary spherocytosis. Blood Cells Mol Dis. 2005 Nov-Dec. 35(3):345-7.

  18. Glader BE, Naumovski L. Hereditary red blood cell disorders. In: Emery AE, Rimoin, DL, eds. Principles and Practice of Medical Genetics. New York, NY:. Churchill Livingstone. 1996.

  19. Hassoun H, Palek J. Hereditary spherocytosis: a review of the clinical and molecular aspects of the disease. Blood Rev. 1996 Sep. 10(3):129-47. [Medline].

  20. Hassoun H, Vassiliadis JN, Murray J, et al. Hereditary spherocytosis with spectrin deficiency due to an unstable truncated beta spectrin. Blood. 1996 Mar 15. 87(6):2538-45. [Medline].

  21. Korones D, Pearson HA. Normal erythrocyte osmotic fragility in hereditary spherocytosis. J Pediatr. 1989 Feb. 114(2):264-6. [Medline].

  22. Lee RD, Glader JN, Lukens JN. In: Lee GR, Foerster J, Lukens J, Paraskevas F, Greer JP, Rodgers GM, eds. Wintrobe's Clinical Hematology. 10th ed. Baltimore, Md: Lippincott Williams & Wilkins; 1999:. 1132-42.

  23. Nakashima K, Beutler E. Erythrocyte cellular and membrane deformability in hereditary spherocytosis. Blood. 1979 Mar. 53(3):481-5. [Medline].

  24. Peters LL, Lux SE. Ankyrins: structure and function in normal cells and hereditary spherocytes. Semin Hematol. 1993 Apr. 30(2):85-118. [Medline].

  25. Rice HE, Oldham KT, Hillery CA, et al. Clinical and hematologic benefits of partial splenectomy for congenital hemolytic anemias in children. Ann Surg. 2003 Feb. 237(2):281-8.

  26. Sackey K. Hemolytic anemia: Part 1. Pediatr Rev. 1999 May. 20(5):152-8; quiz 159. [Medline].

  27. Sackey K. Hemolytic anemia: Part 2. Pediatr Rev. 1999 Jun. 20(6):204-8. [Medline].

  28. Savvides P, Shalev O, John KM, Lux SE. Combined spectrin and ankyrin deficiency is common in autosomal dominant hereditary spherocytosis. Blood. 1993 Nov 15. 82(10):2953-60. [Medline].

  29. Stoehr GA, Stauffer UG, Eber SW. Near-total splenectomy: a new technique for the management of hereditary spherocytosis. Ann Surg. 2005 Jan. 241(1):40-7.

  30. Hsiao M, Sathya C, Nathens AB, de Mestral C, Hill AD, Langer JC. Is activity restriction appropriate for patients with hereditary spherocytosis? A population-based analysis. Ann Hematol. 2013 Apr. 92(4):523-5. [Medline].

 
Previous
Next
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.